评估ATNPD框架与生物体液标志物预测早期帕金森病认知下降
研究基于帕金森病进展标志物计划队列,对364例帕金森病患者和168例对照随访5年,描述脑脊液Aβ42、p-tau181、t-tau及血清NfL的纵向变化,并采用改良ATNPD框架预测认知下降;结果显示脑脊液p-tau181和t-tau在帕金森病中较低且5年内不升高,A+T+N±亚组认知下降更差。
要点
- 帕金森病患者脑脊液p-tau181和t-tau低于对照,5年随访未见升高。
- 帕金森病患者血清NfL随时间增加幅度大于对照。
- ATNPD分类为A+T+N±的帕金森病患者整体MoCA认知下降更差。
核心结论
- 在早期帕金森病患者中,脑脊液p-tau181和t-tau低于对照,且5年随访期间未升高。
- 采用包含脑脊液Aβ42、脑脊液p-tau181和血清NfL的改良ATNPD分类,可识别生物学相关亚组,改善对早期帕金森病认知下降的预测。
研究设计与样本
- 参与者选自帕金森病进展标志物计划队列,临床诊断为散发性帕金森病或为对照,每年随访一次,共5年。
- 采用线性混合效应模型检验诊断与纵向轨迹的交互作用,分析物经对数转换并采用错误发现率校正。
- 在帕金森病患者中,采用线性混合效应模型检验基线ATNPD状态(AD即A+T+N± 对比 非AD)对临床结局的预测,包括蒙特利尔认知评估(MoCA,经秩转换并采用错误发现率校正)。
主要发现
- 帕金森病患者脑脊液p-tau181低于对照(β = -0.16,95% CI -0.23 至 -0.092,p = 2.2e-05),脑脊液t-tau低于对照(β = -0.13,95% CI -0.19 至 -0.065,p = 4e-04)。
- 帕金森病患者与对照的脑脊液Aβ42(p = 0.061)和血清NfL(p = 0.32)差异未达统计学显著。
- 帕金森病患者血清NfL随时间增加幅度大于对照(β = 0.035,95% CI 0.022 至 0.048,p = 9.8e-07);帕金森病患者脑脊液Aβ42(p = 0.18)、p-tau181(p = 1)、t-tau(p = 0.96)的斜率与对照无显著差异。
- ATNPD分类为A+T+N±的帕金森病患者(n = 32;9%)整体MoCA认知下降较所有其他ATNPD状态更差(β = -73,95% CI -110 至 -37,p = 0.00077),包括单纯A+(A+T-N-;n = 75;21%)。
关键数值与推荐
- 改良ATNPD框架定义:A为脑脊液Aβ42,T为脑脊液p-tau181,N为血清NfL。
- AD状态定义为A+T+N±。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: In Parkinson disease (PD), Alzheimer disease (AD) copathology is common and clinically relevant. However, the longitudinal progression of AD CSF biomarkers-β-amyloid 1-42 (Aβ42), phosphorylated tau 181 (p-tau181), and total tau (t-tau)-in PD is poorly understood and may be distinct from clinical AD. Moreover, it is unclear whether CSF p-tau181 and serum neurofilament light (NfL) have added prognostic utility in PD, when combined with CSF Aβ42. First, we describe longitudinal trajectories of biofluid markers in PD. Second, we modified the AD β-amyloid/tau/neurodegeneration (ATN) framework for application in PD (ATNPD) using CSF Aβ42 (A), p-tau181 (T), and serum NfL (N) and tested ATNPD prediction of longitudinal cognitive decline in PD. METHODS: Participants were selected from the Parkinson's Progression Markers Initiative cohort, clinically diagnosed with sporadic PD or as controls, and followed up annually for 5 years. Linear mixed-effects models (LMEMs) tested the interaction of diagnosis with longitudinal trajectories of analytes (log transformed, false discovery rate [FDR] corrected). In patients with PD, LMEMs tested how baseline ATNPD status (AD [A+T+N±] vs not) predicted clinical outcomes, including Montreal Cognitive Assessment (MoCA; rank transformed, FDR corrected). RESULTS: Participants were 364 patients with PD and 168 controls, with comparable baseline mean (±SD) age (patients with PD = 62 ± 10 years; controls = 61 ± 11 years]; Mann-Whitney Wilcoxon: p = 0.4) and sex distribution (patients with PD = 231 male individuals [63%]; controls = 107 male individuals [64%]; χ2: p = 1). Patients with PD had overall lower CSF p-tau181 (β = -0.16, 95% CI -0.23 to -0.092, p = 2.2e-05) and t-tau than controls (β = -0.13, 95% CI -0.19 to -0.065, p = 4e-04), but not Aβ42 (p = 0.061) or NfL (p = 0.32). Over time, patients with PD had greater increases in serum NfL than controls (β = 0.035, 95% CI 0.022 to 0.048, p = 9.8e-07); slopes of patients with PD did not differ from those of controls for CSF Aβ42 (p = 0.18), p-tau181 (p = 1), or t-tau (p = 0.96). Using ATNPD, PD classified as A+T+N± (n = 32; 9%) had worse cognitive decline on global MoCA (β = -73, 95% CI -110 to -37, p = 0.00077) than all other ATNPD statuses including A+ alone (A+T-N-; n = 75; 21%). DISCUSSION: In patients with early PD, CSF p-tau181 and t-tau were low compared with those in controls and did not increase over 5 years of follow-up. Our study shows that classification using modified ATNPD (incorporating CSF Aβ42, CSF p-tau181, and serum NfL) can identify biologically relevant subgroups of PD to improve prediction of cognitive decline in early PD.
引用
- Cousins KAQ, Irwin DJ, Tropea TF, et al. Evaluation of ATNPD Framework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson Disease. Neurology. 2024. PMID: 38306599. doi:10.1212/WNL.0000000000208033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。